Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2009
DOI:
https://doi.org/10.33321/cdi.2010.34.7Keywords:
AEFI, surveillance, immunisation, vaccine safetyAbstract
The adverse events following immunisation surveillance aims to monitor vaccine and immunisation program safety and to detect population-specific, rare, late-onset or unexpected adverse events that may not be detected in pre-licensure vaccine trials. This report summarises national passive surveillance data reported to 31 August 2009 for adverse events following immunisation (AEFI) in children aged less than 7 years who received vaccines between 1 January and 30 June 2009.
Downloads
References
National Health and Medical Research Council. The Australian Immunisation Handbook. 9th edn. Canberra: Australian Government Department of Health and Ageing, 2008.
Department of health and Human Services, Victoria. Immunisation newsletter. Accessed on January 2009. Available from: http://www.health.vic.gov.au/data/assets/pdffile/0015/130083/immunisation-newsletter-issue-32.pdf
Immunisation section Department of Health, South Australia, Quarterly newsletter. Accessed on January 2009. Available from: http://www.dh.sa.gov.au/pehs/Immunisation/0803-sharp-point-news.pdf
Queensland Department of Health. National Immunisation Program Schedule change for Queensland. Accessed January 2009. Available from: http://www.health.qld.gov.au/ph/Documents/cdb/imm sched gp.pdf
Centers for Disease Control and Prevention. Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for Hib surveillance—United States, 2008. MMWR Morb Mortal Wkly Rep 2008;57(46):1252–1255.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003;27(3):307–323.
Lawrence GL, Mahajan D, Roomiani I. Supplementary report: surveillance of adverse events following immunisation among children aged < 7 years in Australia,1 January to 30 June 2008. Commun Dis Intell 2009;33(1):27–31.
Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008;32(4):371–387.
Lawrence GL, Aratchige PE, Hill R. Supplementary report: surveillance of adverse events following immunisation among children aged < 7 years in Australia, 1 January to 30 June 2007. Commun Dis Intell 2007;31(4):379–382.
Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2006. Commun Dis Intell 2006;30(4):438–442.
State Government of Victoria, Department of Human Services. SAEFVIC: Surveillance of adverse events following vaccination in the community. State Government of Victoria, 2008. Accessed on September 2009. Available from: http://www.health.vic.gov.au/immunisation/general/saefvic
Pym M, Adams J, Booy R, et al. The development and trial of paediatric active enhanced disease surveillance (PAEDS): A new surveillance mechanism for Australia. Presented at the Royal Australasian College of Physicians Congress, Adelaide, 11–15 May 2008.
Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003;179(4):191–194.
Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105(1):e12. Available from: http://pediatrics.aappublications.org/cgi/reprint/105/1/e12.pdf
Kramarz P, France EK, DeStefano F, Black SB, Shinefield H, Ward JI, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;20(4):410–416.
Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. [erratum in N Engl J Med 2001;344(20):1564]. N Engl J Med 2001;344(8):564–572.
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Costa Clemens S, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11–22.
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23–33.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2010 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
